Proteomics analysis revealed that SPI1 may serve as a pivotal transcriptional factor that enhances PD-L1 expression by acting as a downstream effector of PRDM1. Previous studies have revealed that SPI1 upregulation suppresses tumor growth in MYC-deregulated B cell lymphomas, acute myeloid leukemia, and leukemia. Here, PRDM1 is linked to B-cell non-Hodgkin lymphoma.